FrancophonIA/ELRC3.0 huggingface dataset:
English: If you are in a clinical trial or compassionate use programme and need more information about your treatment, contact the doctor who is giving it to you.
Slovenian: Če ste vključeni v klinično preizkušanje ali program sočutne uporabe ter potrebujete več podatkov o vašem zdravljenju, se obrnite na zdravnika, ki vam je zdravljenje predpisal.
English: The letter from the Company notifying the EMEA of the withdrawal of DepoCyte is available here.
Slovenian: Dopis, s katerim je podjetje obvestilo EMEA o umiku zdravila DepoCyte, je na voljo tukaj.
English: QUESTIONS AND ANSWERS ON WITHDRAWAL OF APPLICATION FOR A VARIATION OF MARKETING AUTHORISATION for DEPOCYTE
Slovenian: VPRAŠANJA IN ODGOVORI GLEDE UMIKA VLOGE ZA SPREMEMBO DOVOLJENJA ZA PROMET za zdravilo DEPOCYTE
English: Cytarabine has been used as an anti-cancer medicine since the 1970s.
Slovenian: Citarabin je v uporabi kot zdravilo proti raku že od 1970-ih dalje.
English: There are no consequences for DepoCyte's use in the indications for which it is already authorised, where the known benefit and risk remain unchanged.
Slovenian: Omenjeno nima posledic za uporabo zdravila DepoCyte za indikacije, za katere je bilo zdravilo že odobreno in pri katerih ostajajo koristi in tveganja nespremenjeni.
English: DepoCyte helps control the symptoms of the disease.
Slovenian: Zdravilo DepoCyte pomaga obvladovati simptome bolezni.
English: The studies measured how long it would take before the disease would progress.
Slovenian: Raziskavi sta merili čas do napredovanja bolezni.
English: Following CHMP opinion, it usually takes around 6 weeks for the European Commission to update the licence.
Slovenian: Ko CHMP poda mnenje, Evropska komisija v približno 6 tednih posodobi dovoljenje.
English: The company has informed the CHMP that the decision has no consequences for patients enrolled in clinical trials or compassionate use programmes.
Slovenian: Podjetje je obvestilo CHMP, da odločitev nima posledic za bolnike, ki so vključeni v klinična preizkušanja ali programe sočutne uporabe.
English: The company presented the results of two studies, involving 164 patients with solid tumour neoplastic meningitis.
Slovenian: Podjetje je predstavilo izsledke dveh raziskav, ki sta zajemali 164 bolnikov z neoplastičnim meningitisom zaradi trdnega tumorja.
English: On 28 June 2006, SkyePharma PLC officially notified the Committee for Medicinal Products for Human Use (CHMP) that they wish to withdraw their application for a new indication for DepoCyte 50 mg suspension for injection, in the intrathecal treatment of solid tumour neoplastic meningitis.
Slovenian: Podjetje SkyePharma PLC je 28. junija 2006 uradno obvestilo Odbor za zdravila za uporabo v humani medicini (CHMP), da želi umakniti vlogo za novo indikacijo za zdravilo DepoCyte 50 mg suspenzijo za injiciranje, ki se uporablja pri intratekalnem zdravljenju neoplastičnega meningitisa zaradi trdnega tumorja.
English: What are the consequences of the withdrawal for patients undergoing clinical trials / compassionate use programmes with DepoCyte?
Slovenian: Kakšne so posledice umika za bolnike, ki sodelujejo v kliničnih preizkušanjih / programih sočutne uporabe zdravila DepoCyte?
English: DepoCyte was to be injected intrathecally.
Slovenian: Zdravilo DepoCyte naj bi se vbrizgavalo intratekalno.
English: The CHMP had concerns that the studies presented by the Company had not sufficiently shown that Depocyte was as effective as, or more effective than intrathecal methotrexate.
Slovenian: CHMP je imel zadržke, da raziskave, ki jih je predstavilo podjetje, niso v zadostni meri dokazale, da je zdravilo DepoCyte enako ali bolj učinkovito kot intratekalni metotreksat.
English: DepoCyte is a suspension for injection that contains 50 mg of the active substance cytarabine.
Slovenian: Zdravilo DepoCyte je suspenzija za injiciranje, ki vsebuje 50 mg zdravilne učinkovine citarabin.
English: What is happening for DepoCyte for the treatment of lymphomatous meningitis?
Slovenian: Kaj to pomeni za nadaljnjo uporabo zdravila DepoCyte za zdravljenje limfomatoznega meningitisa?
English: The application was at Day 90 when the Company withdrew.
Slovenian: Podjetje je umaknilo vlogo na 90. dan postopka.
English: DepoCyte is injected directly into the nervous system, in the space between the lining of the spinal cord and brain (intrathecal injection).
Slovenian: Zdravilo DepoCyte se vbrizga naravnost v živčni sistem, v prostor med ovojnice hrbtenjače in možganov (intratekalno vbrizgavanje).
English: Therefore, at the time of the withdrawal, the CHMP's view was that it had not been shown that the benefits of DepoCyte in the treatment of solid tumour neoplastic meningitis were greater that its risks.
Slovenian: Zato je bil v času umika vloge CHMP mnenja, da ni bilo dokazano, da so koristni učinki zdravila DepoCyte pri zdravljenju neoplastičnega meningitisa zaradi trdnega tumorja večji od z njim povezanih tveganj.
English: DepoCyte was compared with methotrexate (another anti-cancer medicine), both medicines being administered intrathecally.
Slovenian: V njih so zdravilo DepoCyte primerjali z zdravilom metotreksat (prav tako zdravilo proti raku), obe zdravili pa sta bili dajani intratekalno.
English: Based on the review of the data at the time of the withdrawal, the CHMP had concerns and was of the provisional opinion that DepoCyte could not be approved for the intrathecal treatment of solid tumour neoplastic meningitis.
Slovenian: Na podlagi podatkov na razpolago v času umika je imel CHMP zadržke in bil začasnega mnenja, da zdravilo DepoCyte ne more biti odobreno za intratekalno zdravljenje neoplastičnega meningitisa zaradi trdnega tumorja.
English: It is a cytotoxic (a medicine that kills cells that are dividing, such as cancer cells) that belongs to the group of anti-metabolites.
Slovenian: Zdravilo je citotoksin (zdravilo, ki ubija deleče se celice, kakršne so rakaste celice), ki spada v skupino antimetabolitov.
English: What was DepoCyte expected to be used for?
Slovenian: Za kaj naj bi se zdravilo DepoCyte uporabljalo?
English: DepoCyte contains cytarabine in a special formulation: the active substance is contained in liposomes (small fatty particles) from which it is slowly released.
Slovenian: Zdravilo DepoCyte vsebuje citarabin v posebni formulaciji: zdravilna učinkovina se nahaja v liposomih (majhnih maščobnih delcih), iz katerih se počasi sprošča.
English: DepoCyte was to be used in the treatment of solid tumour neoplastic meningitis: this is a disease where cancer cells, originally from a solid tumour (such as lung or breast cancer), spread to the membranes of the nervous system.
Slovenian: Zdravilo DepoCyte je bilo namenjeno za uporabo pri zdravljenju neoplastičnega meningitisa zaradi trdnega tumorja: pri tej bolezni se rakaste celice, ki izvirajo iz trdnega tumorja (kot npr. rak pljuč ali dojke), razširijo na membrane živčnega sistema.
English: London, 29 June 2006 Doc.Ref.
Slovenian: London, 29.06.06 Sklic dok.
English: The active substance in DepoCyte, cytarabine, is an anti-cancer agent.
Slovenian: Zdravilna učinkovina v zdravilu DepoCyte, citarabin, je učinkovina proti raku.
English: How is DepoCyte expected to work?
Slovenian: Kako naj bi zdravilo DepoCyte delovalo?
English: DepoCyte is used to treat lymphomatous meningitis: this is a condition where lymphoma tumour cells have spread to the membranes that surround the nervous system (meninges).
Slovenian: Zdravilo DepoCyte se uporablja za zdravljenje limfomatoznega meningitisa: to je stanje, v katerem so se tumorske celice limfoma razširile na membrane, ki obdajajo živčni sistem (meninge).
English: 06 August 2014
Slovenian: 6. avgust 2014
English: The European Commission issued a decision on 06 August 2014.
Slovenian: Evropska komisija je izdala odločbo dne 6. avgusta 2014.
English: This is a procedure where one European country (the ‘reference Member State', in this instance the United Kingdom) assesses a medicine with a view to granting a marketing authorisation that will be valid in this country as well as in other European countries (the ‘concerned Member States', in this instance Denmark, Finland, Ireland, Luxembourg, the Netherlands, Norway, Spain, and Sweden).
Slovenian: To je postopek, v katerem ena evropska država („referenčna država članica“, v tem primeru Združeno kraljestvo) oceni zdravilo zato, da se izda dovoljenje za promet, ki bo veljalo v tej državi in drugih evropskih državah („zadevnih državah članicah“, v tem primeru na Danskem, Finskem, Irskem, v Luksemburgu, na Nizozemskem, Norveškem, v Španiji in na Švedskem).
English: On 22 May 2014, the European Medicines Agency completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Dexamed (dexamfetamine sulphate).
Slovenian: Evropska agencija za zdravila je dne 22. maja 2014 zaključila arbitražni postopek po nestrinjanju med državami članicami Evropske unije (EU) glede odobritve zdravila Dexamed (deksamfetaminijev sulfat).
English: Why was Dexamed reviewed?
Slovenian: Zakaj je bilo zdravilo Dexamed pregledano?
English: However, the Member States were not able to reach an agreement and the UK medicines regulatory agency referred the matter to the CHMP for arbitration on 10 June 2013.
Slovenian: Vendar države članice niso mogle doseči soglasja, zato je regulativna agencija Združenega kraljestva za zdravila 10. junija 2013 zadevo napotila na odbor CHMP v arbitražo.
English: Dexamed is a medicine that contains the active substance dexamfetamine sulphate.
Slovenian: Dexamed je zdravilo, ki vsebuje zdravilno učinkovino deksamfetaminijev sulfat.
English: These conclusions were supported by a group of experts in childhood and adolescent behavioural problems consulted by the CHMP.
Slovenian: Te zaključke je podprla tudi skupina izvedencev na področju vedenjskih motenj v otroštvu in mladostništvu, s katero se je posvetoval odbor CHMP.
English: ADHD is a condition that mainly affects children, resulting in a persistent inability to concentrate, hyperactivity and impulsive behaviour.
Slovenian: ADHD je bolezen, ki v glavnem prizadene otroke in povzroči stalno nezmožnost koncentracije, hiperaktivnost ter impulzivno vedenje.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Dexamed outweigh its risks, and the marketing authorisation can be granted in the United Kingdom and in the following countries: Denmark, Finland, Ireland, Luxembourg, the Netherlands, Norway, Spain and Sweden.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Dexamed večje od z njim povezanih tveganj in da se dovoljenje za promet lahko izda v Združenem kraljestvu in naslednjih državah: na Danskem, Finskem, Irskem, v Luksemburgu, na Nizozemskem, Norveškem, v Španiji in na Švedskem.
English: Educational material will also be given to pharmacists, parents and carers to help them identify any potential abuse or improper use of Dexamed.
Slovenian: Prav tako bodo izobraževalno gradivo prejeli farmacevti, starši in negovalci, da bodo lažje prepoznali morebitno zlorabo ali napačno uporabo zdravila Dexamed.
English: Furthermore, the company that markets Dexamed will conduct additional studies on the risk of abuse for this medicine.
Slovenian: Poleg tega bo družba, ki trži zdravilo Dexamed, izvedla dodatne študije o tveganju za zlorabo tega zdravila.
English: Dexamfetamine belongs to a group of medicines called ‘psychostimulants' and is thought to work by activating certain areas of the brain that control attention and concentration, thus helping to reduce impulsive behaviour.
Slovenian: Deksamfetamin spada v skupino zdravil, imenovanih „psihostimulansi“, in domnevno deluje tako, da aktivira določene dele možganov, ki nadzorujejo pozornost in koncentracijo, s čimer pomaga zmanjšati impulzivno vedenje.
English: These measures include starting and regularly monitoring treatment with Dexamed under the supervision of a doctor experienced in treating childhood and adolescent behaviour disorders.
Slovenian: Ti ukrepi vključujejo uvedbo in redno spremljanje zdravljenja z zdravilom Dexamed pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem vedenjskih motenj pri otrocih in mladostnikih.
English: It is to be available as tablets (5 mg) for the treatment of children between 6 and 17 years of age who have attention deficit hyperactivity disorder (ADHD) and in whom methylphenidate (another medicine for ADHD) was not effective (second-line treatment).
Slovenian: Na voljo naj bi bilo v obliki tablet (5 mg) za zdravljenje otrok, starih od 6 do 17 let, ki imajo primanjkljaj pozornosti in motnjo hiperaktivnosti (attention deficit hyperactivity disorder - ADHD) ter pri katerih metilfenidat (drugo zdravilo za ADHD) ni bilo učinkovito (zdravilo druge izbire).
English: Educational material will be provided to doctors to help them decide if treatment with Dexamed is appropriate and to monitor patients receiving the medicine.
Slovenian: Zdravniki bodo prejeli izobraževalno gradivo, da bodo lažje presodili, ali je zdravljenje z zdravilom Dexamed primerno, in spremljali bolnike, ki bodo prejemali zdravilo.
English: Kohne Pharma GmbH submitted Dexamed to the UK medicines regulatory agency for a decentralised procedure.
Slovenian: Družba Kohne Pharma GmbH je regulativni agenciji Združenega kraljestva za zdravila predložila vlogo za začetek decentraliziranega postopka za zdravilo Dexamed.
English: Although the CHMP acknowledged that there is a risk of abuse and dependence with Dexamed, it concluded that the risk minimisation measures proposed to mitigate this risk are adequate.
Slovenian: Čeprav je odbor CHMP potrdil, da pri uporabi zdravila Dexamed obstaja tveganje za zlorabo in odvisnost, je zaključil, da so ukrepi, ki so bili predlagani za zmanjšanje teh tveganj, zadostni.
English: The CHMP also noted that evidence from studies and clinical practice is available to show that dexamfetamine is effective in ADHD, including in patients in whom other treatments have failed.
Slovenian: Odbor CHMP je upošteval tudi dejstvo, da so na voljo dokazi iz študij in klinične prakse, ki kažejo, da je deksamfetamin učinkovit pri ADHD, tudi pri bolnikih, pri katerih zdravljenje z drugimi zdravili ni bilo uspešno.
English: What is Dexamed?
Slovenian: Kaj je zdravilo Dexamed?
English: Therefore, based on evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the benefits of Dexamed outweigh its risks for second-line treatment of ADHD and recommended that the marketing authorisation be granted in all concerned Member States.
Slovenian: Zato je na podlagi ocene trenutno razpoložljivih podatkov in interne znanstvene razprave odbor CHMP zaključil, da so koristi zdravila Dexamed večje od z njim povezanih tveganj, kadar se uporablja kot zdravilo druge izbire za ADHD, in priporočil, da se zanj izda dovoljenje za promet v vseh zadevnih državah članicah.
English: The grounds for the referral were concerns raised by the Netherlands that Dexamed presents a higher risk for abuse and dependence compared with other ADHD treatments, and that the data submitted to support the application did not provide sufficient evidence to demonstrate its effectiveness as a second-line treatment for ADHD.
Slovenian: Podlaga za napotitev so bili zadržki Nizozemske, ki je menila, da zdravilo Dexamed predstavlja večje tveganje za zlorabo in odvisnost v primerjavi z drugimi zdravili za ADHD in da podatki, predloženi v podporo vlogi, niso zagotovili zadostnih dokazov, da bi lahko potrdili njegovo učinkovitost kot zdravila druge izbire za ADHD.
English: The experts' group advised that while there is some evidence that medicines of the same type as Dexamed are more likely to induce dependence than other treatments for ADHD, based on clinical practice the risk of developing dependence in patients treated with dexamfetamine is considered to be low and could be adequately managed with appropriate risk minimisation measures.
Slovenian: Skupina izvedencev je menila, da nekateri dokazi sicer kažejo, da pri zdravilih iste vrste, kot je zdravilo Dexamed, obstaja večja verjetnost za odvisnost kot pri drugih zdravilih za ADHD, vendar se na podlagi klinične prakse ocenjuje, da je tveganje za razvoj odvisnosti pri bolnikih, ki se zdravijo z deksamfetaminom, majhno in ga je mogoče zadovoljivo obvladati z ustreznimi ukrepi za zmanjšanje tveganja.
English: MA (EU) Number (Invented) name Strength
Slovenian: (Izmišljeno) ime Jakost
English: Date of first authorisation: 17 May 2002 Date of latest renewal: 17 May 2007
Slovenian: Datum prve pridobitve dovoljenja: 17 maj 2002 Datum zadnjega podaljšanja dovoljenja: 17 maj 2007
English: Axura is not recommended for children and adolescents under the age of 18 years.
Slovenian: Zdravila Axura ne priporočajo otrokom in mladostnikom, mlajšim od 18 let.
English: Axura with food and drink
Slovenian: Zdravilo Axura skupaj s hrano in pijačo
English: The safety and efficacy of Axura in children aged below 18 years has not been established.
Slovenian: Varnost in učinkovitost zdravila Axura pri otrocih, starih manj kot 18 let, nista bili dokazani.
English: Detailed information on this medicinal product is available on the website of the European Medicines Agency (EMA) http://www.ema.europa.eu.
Slovenian: Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
English: - If you find you have forgotten to take your dose of Axura, wait and take your next dose at the usual time.
Slovenian: - ce ste ugotovili, da ste pozabili vzeti predpisani odmerek zdravila Axura, počakajte in vzemite naslednji odmerek ob običajnem času.
English: Once daily
Slovenian: Enkrat dnevno
English: Other medicines and Axura
Slovenian: Druga zdravila in zdravilo Axura
English: The Axura treatment initiation pack is only to be used for the beginning of the treatment with Axura.
Slovenian: Začetni paket za zdravljenje z zdravilom Axura se uporablja samo za začetek zdravljenja s tem zdravilom.
English: At the beginning of treatment you will start by using Axura 5 mg film-coated tablets once a day.
Slovenian: Na začetku boste zdravljenje začeli z jemanjem zdravila Axura 5 mg filmsko obložene tablete enkrat dnevno.
English: Axura belongs to a group of medicines known as anti-dementia medicines.
Slovenian: Zdravilo Axura sodi v skupino zdravil, znanih kot zdravila za zdravljenje demence.
English: In postmarketing experience these events have been reported in patients treated with Axura.
Slovenian: V okviru postmarketinških izkušenj so te dogodke navajali pri bolnikih, zdravljenih z zdravilom Axura.
English: If you go into hospital, let your doctor know that you are taking Axura.
Slovenian: V primeru, da ste sprejeti v bolnišnico, obvestite zdravnika, da jemljete zdravilo Axura.
English: What you need to know before you take Axura Do not take Axura
Slovenian: Kaj morate vedeti, preden boste vzeli zdravilo Axura Ne jemljite zdravila Axura
English: In particular, Axura may change the effects of the following medicines and their dose may need to be adjusted by your doctor:
Slovenian: Posebno v primeru, da skupaj z zdravilom Axura jemljete naslednja zdravila, se učinki le teh lahko spremenijo in bo morda vaš zdravnik moral prilagoditi odmerek:
English: - If you take a large overdose of Axura, contact your doctor or get medical advice, as you may need medical attention.
Slovenian: - V primeru, da ste zaužili prevelik odmerek zdravila Axura, obvestite svojega zdravnika ali se obrnite po nasvet na zdravstveno službo, ker boste morda potrebovali zdravniško obravnavo.
English: In short term studies in rats memantine like other NMDA-antagonists have induced neuronal vacuolisation and necrosis (Olney lesions) only after doses leading to very high peak serum concentrations.
Slovenian: V kratkotrajnih študijah na podganah je memantin, tako kot drugi antagonisti receptorjev NMDA, povzročil nastanek vakuol in nekrozo v nevronih (Olneyeve lezije), vendar le pri odmerkih, ki dajo zelo visoko maksimalno plazemsko koncentracijo.
English: If you forget to take Axura
Slovenian: Če ste pozabili vzeti zdravilo Axura
English: The recommended treatment dose of 20 mg per day is achieved by a gradual increase of the Axura dose during the first 3 weeks of treatment.
Slovenian: Priporočeni zdravilni odmerek 20 mg na dan se doseže s postopnim povečevanjem odmerka zdravila Axura med prvimi tremi tedni zdravljenja.
English: MARKETING AUTHORISATION NUMBER(S) 13.
Slovenian: ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET 13.
English: The most frequently occurring adverse reactions with a higher incidence in the Axura group than in the placebo group were dizziness (6.3% vs 5.6%, respectively), headache (5.2% vs 3.9%), constipation (4.6% vs 2.6%), somnolence (3.4% vs 2.2%) and hypertension (4.1% vs 2.8%).
Slovenian: Najpogostejši neželeni učinki, ki so se pogosteje pojavili pri skupini bolnikov, ki je jemala zdravilo Axura,kot pri skupini, ki je prejemala placebo, so bili omotica (6,3 % proti 5,6 %), glavobol (5,2 % proti 3,9 %), zaprtje (4,6 % proti 2,6 %), zaspanost (3,4 % proti 2,2 %) in hipertenzija (4,1 % proti 2,8 %).
English: Continue to take Axura as long as it is of benefit to you.
Slovenian: Jemljite zdravilo Axura tako dolgo, kot vam pomaga.
English: Content of the pack and other information What Axura contains
Slovenian: Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Axura
English: EU/1/02/218/011 500 ml (10 bottles of 50 ml)
Slovenian: EU/1/02/218/011 500 ml (10 x 50 ml)
English: If you take more Axura than you should
Slovenian: Če ste vzeli večji odmerek zdravila Axura, kot bi smeli
English: Furthermore, Axura has minor to moderate influence on the ability to drive and use machines such that outpatients should be warned to take special care.
Slovenian: Prav tako ima zdravilo Axura majhen do zmerno velik vpliv na sposobnost vožnje in upravljanja s stroji, zato je potrebno bolnike opozoriti na posebno previdnost.
English: Fatigue 1 Hallucinations have mainly been observed in patients with severe Alzheimer´s disease.
Slovenian: Utrujenost 1 Halucinacije so bile večinoma opažene pri bolnikih s hudo Alzheimerjevo boleznijo.
English: Adverse reactions are ranked according to system organ class, using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to
Slovenian: Neželeni učinki so razporejeni glede na organske sisteme ob uporabi naslednjih navedb: zelo pogosti (≥1/10); pogosti (≥1/100 do <1/10); občasni (≥1/1.000 do <1/100); redki (≥1/10.000 do <1/1.000); zelo redki (<1/10.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
English: What Axura is and what it is used for What you need to know before you take Axura How to take Axura
Slovenian: Kaj je zdravilo Axura in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Axura Kako jemati zdravilo Axura
English: Additional for 15 mg and 20 mg film-coated tablets: Iron oxide yellow and red (E 172)
Slovenian: Dodatno za 15 mg in 20 mg filmsko obložene tablete: rumeni in rdeči železov oksid (E 172)
English: shortness of breath, high blood pressure and drug hypersensitivity
Slovenian: visok krvni tlak in preobčutljivost za zdravilo
English: In clinical trials in mild to severe dementia, involving 1,784 patients treated with Axura and 1,595 patients treated with placebo, the overall incidence rate of adverse reactions with Axura did not differ from those with placebo; the adverse reactions were usually mild to moderate in severity.
Slovenian: V kliničnih preskušanjih bolnikov z zmerno do hudo demenco, ki so zajeli 1784 bolnikov, zdravljenih z zdravilom Axura in 1595 bolnikov, ki so prejemali placebo, se skupna incidenca neželenih učinkov pri zdravilu Axura ni razlikovala od placeba, neželeni učinki pa so bili po resnosti večinoma blagi do zmerni.
English: Axura acts on these NMDA-receptors improving the transmission of nerve signals and the memory.
Slovenian: Zdravilo Axura deluje na receptorje NMDA in izboljša prenos živčnih signalov in spomin.
English: Axura belongs to a group of medicines called NMDAreceptor antagonists.
Slovenian: Axura spada v skupino zdravil, ki se imenujejo antagonisti receptorjev NMDA.